The fully CE certified ITM Rhenium-PTA/PTCA™ is routinely provided to patients with progressed peripheral and cardiac endovascular disease (restenosis and in-stent restenosis).

The ITM Rhenium-PTA/PTCA™ is approved as a medical device and has received full CE-certification for the use in peripheral and cardiovascular applications in 2008. Data from routine clinical use (registries) shows that the restenosis rate, even in patients with previously untreatable large lesions and progressed stages, could be reduced from 70-80% to 10-15% through this new generation of endovascular brachytherapy.

With this new generation of brachytherapy, a missing, effective, therapy option especially for a growing number of diabetic patients with progressed peripheral endovascular disease is provided.